Neuronetics and Transformations Care Network Announce Extended Commercial Partnership
Neuronetics, Inc. (NASDAQ: STIM) has announced an extended commercial partnership with Transformations Care Network, enhancing access to NeuroStar systems, which provide transcranial magnetic stimulation (TMS) for mental health treatment. The partnership aims to support the growing number of Americans facing mental health disorders, facilitating better patient access to care. Neuronetics, a leader in TMS technology, emphasizes its commitment to improving quality of life through non-invasive treatment options backed by extensive clinical research.
- Extended partnership with Transformations Care Network to increase access to NeuroStar systems.
- Neuronetics is a leader in TMS technology with over 4.5 million treatments delivered.
- The partnership supports efforts to assist a growing population with mental health disorders.
- None.
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today announced an extended commercial partnership with Transformations Care Network (“Transformations”), one of the nation’s largest mental healthcare providers. Under the agreement, the Transformations Care Network will continue to expand upon its multi-state footprint of NeuroStar systems.
“We are very excited to be extending our commercial partnership with Transformations, a long-standing customer that is one of the country’s largest providers of mental health care,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “With the continued increase in the number of Americans suffering from mental health disorders, it is critical that we do all we can to support our customers’ efforts to increase patient access to effective care. We look forward to continuing to be a foundational component of Transformations’ TMS solution.”
“Finding the most effective treatment for a mental health condition looks different for everyone. TMS can be a highly successful tool for patients suffering from neurohealth disorders that are not responding to other evidence-based treatments,” said Brian Wheelan, Chief Executive Officer of Transformations. “We are thrilled to expand our relationship with Neuronetics, the leading provider of TMS devices, as we continue to grow our TMS offering and help more patients and their families find relief.”
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from neurohealth conditions. An FDA-cleared, non-drug, noninvasive treatment for people with depression and OCD, Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder in adults with over 4.5 million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit NeuroStar.com.
About Transformations Care Network
Transformations is a growing network of outpatient mental health clinics that focuses on delivering timely access to high quality psychiatry and therapy services. We offer a hybrid of in-person and telehealth services to best serve the needs of the communities in which we reside.
Formed in 2020, Transformations currently operates across Massachusetts, Pennsylvania, Virginia, Maryland, Washington and West Virginia. At 30+ locations and 800+ clinicians, we create a supportive environment for our clinicians and staff so that they can focus on providing a welcoming experience and the care and services that our clients need to improve their lives.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
What is the significance of Neuronetics' partnership with Transformations Care Network?
What is the stock symbol for Neuronetics?
How many treatments has Neuronetics delivered using NeuroStar?
What technology does Neuronetics offer for mental health treatment?
Which states does Transformations Care Network operate in?
